Drugs / Inactivated HAV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01865968 | Oct 2008 → Dec 2011 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | Results 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗
按0、6月程序接种两剂甲肝灭活疫苗后15年，孩尔来福 ® 组的平均抗体水平为164.8mIU/ml，对照组为105.7mIU/ml，血清保护率方面，两款疫苗分别为97.9%和94.7%。 |
| 2020-03-30 | Sinovac Biotech Co., Ltd | Results 儿童接种孩尔来福 ® 后11年随访研究显示：甲肝灭活疫苗能至少提供30年的有效保护 sinovac.com ↗
此外，研究者还利用数学模型预测两种疫苗的免疫持久性，结果显示两种疫苗均能至少提供30年的有效保护。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗ |
| 2020-03-30 | Sinovac Biotech Co., Ltd | 儿童接种孩尔来福 ® 后11年随访研究显示：甲肝灭活疫苗能至少提供30年的有效保护 sinovac.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated HAV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865968 ↗ |
| Known as | Healive | “A randomized clinical trial of hepatitis A vaccines (1 or 2 doses of inactivated vaccine [Healive] or 1 dose of live attenuated vaccine [Biovac]) was conducted among adults to...” PMID 25969561 ↗ May 2015 |
| Modality | Vaccine | “A randomized clinical trial of hepatitis A vaccines” PMID 25969561 ↗ May 2015 |
| Route | Intramuscular | “Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.” NCT01865968 ↗ |